Enteral and parenteral nutrition – critically ill patients In lefall of the EN

Ioana Grintescu

Liliana Mirea, Raluca Ungureanu, Ioana Cristina Grintescu, Daniel Mirea

Clinical Emergency Hospital of Bucharest

Carol Davila University of General Medicine, Bucharest








 Nutrition of Intestinal Mucosa 						
	Luminal Nutrition	Main Substrates				
Small Bowel Colon	30% 80%	Glutamin SCFA's				

• • Lack of endoluminal substrates

↑intestinal permeability
 ↓villous height ⇒ malabsorption, an impaired ability to act as a barrier (endogenous bacteria and toxins)



Lack of endoluminal substrates

 Intestinal epithelial cell apoptosis, villiand crypt atrophy during PN, even if energy requirements are covered by 100%

 Supports the concept that rather lack of endoluminal substrates than TPN per se is responsible for many of the adverse events seen in patients fed with TPN

Sun X et al. JPEN J Parenter Enteral Nutr. 2006;30:474-9



- o ↓stress ulcer
- *întestinal peristalsis*
- \downarrow risk of colonization
- Thormonal intestinal function



 Reduction of lymphotoxin-β-receptor expression by TPN

• Evidence that **TPN** *per se* (not only lack of EN) **impairs GALT and mucosal immunity**

Kang W et al. Ann Surg. 2006;244:392-399

Failure of Enteral Nutrition

 Immunological alterations and impairment of "gut associated lymphatic tissue" (GALT)

- Bowel becomes source of activated cells and pro-inflammatory stimuli during "gut starvation"
- Secondary changes in permeability and maybe bacterial translocation challenge GALT

Kudsk KA. Am J Surg 2003;185:16–21

Positive Effects of EN

- IgA-levels and number of circulating lyphocytes of GALT are positively influenced by EN
 - Lymphocytes migrate in non-intestinal tissue (i.e. lung) and modify immune response
 - Neuroendocrine system-/bacteria-hostinteraction of the gut influences regulation of inflammation also outside of the GI tract

Kudsk KA, Am J Surg 2002, 183:390-393 Luyer MD, et al. J Exp Med 2005, 202:1023-1029



EN if ever possible (T)PN only if EN not possible or insufficient

EN contraindications

- Absolut CI
 - Immediate postoperatively or after trauma
 - Shock status (severe acidosis)
 - Severe hypoxia
- Relative CI
 - Dynamic ileus
 - Severe vomiting
 - High quantity of gastric aspirate (> 1200 ml/24h)
 - Severe diarrhea
 - Abdominal hypertension
 - Abdominal dysfunction

• • EN contraindications

But TPN is permitted

- Mesenteric ischemia
- Mechanical ileus
- Acute abdominal pain
- Abdominal compartment syndrome

• • Timing of EN

Metaanalysis of 6 RCT 's with 234 patients

- Chiarelli A, Enzi G, Casadei A, et al. Very early nutrition supplementation in burned patients. Am J Clin Nutr. 1990;51:1035–1039
- Chuntrasakul C, Chinswangwatanakul V, Chockvivatanavanit S. Early nutritional support in severe traumatic patients. J Med Assoc Thai. 1996;79:21–25 Pupelis G, Selga G, Austrums E, Kaminski A. Jejunal feeding, even when instituted late, improves outcomes in patients with severe pancreatitis and peritonitis. Nutrition. 2001;17:91–94. doi: 10.1016/S0899-9007(00)00508-6
- Kompan L, Kremzar B, Gadzijev E, Prosck M. Effects of early enteral nutrition on intestinal permeability and the development of multiple organ failure after multiple injury. Intensive Care Med. 1999;25:157–161. doi: 10.1007/s001340050809]
- Pupelis G, Austrums E, Jansone A, Sprucs R, Wehbi H. Randomised trial of safety and efficacy of postoperative enteral feeding in patients with severe pancreatitis: preliminary report. Eur J Surg. 2000;166:383–387. doi: 10.1080/11024150075000893
- Kompan L, Vidmar G, Spindler-Vesel A, Pecar J. Is early enteral nutrition a risk factor for gastric intolerance and pneumonia? Clin Nutr. 2004;23:527–532. doi: 10.1016/j.clnu.2003.09.013

• • Timing of EN

• Start with EN < 24 h vs > 24 h

Results

 Significant reduction in mortality (OR 0.34, 95% CI 0.14-0.85) and incidence in pneumonias (OR 0.31, CI 0.12-0.78)

Early vs. Late EN: Mortality

Review: Endy ExtensiV Administry of delayed nutrient intale Comparison: ID Early EN vs. delayed nutrient intale Outcome ID Notativ

3uty Il sécsityon	Sety Bi nili	lebyci ni	RP()andon) 99% O	Yegt S	FB (ramba) 956-0	Yer
Nore	103	2/31	+ +	- 3.E	0.48 (0.05, 5.01)	1396
Crutecalul	1/21	3)17	+	5.91	0.27 (0.06, 2.37)	1596
Shiph	4,121	4/12		17.82	1.05 [0.30, 3.66]	1998
Pupels 2001	1011	5/18	+ +	6.88	0.33 [0.04, 2.45]	1990
Fuete	1/30	1/38	++	6.74	0.14 (0.02, 1.08)	1993
Nehota	12/110	16(110		17.61	0.75 (0.97, 1.50)	1914
Tai (SNO)	215	113	-	300.00	0.61 (0.37, 1.06)	
Table ents 31 Ent/201	37 (Celayec)					
Test for felecostety, Chi ²	+11, #=5(P=0.54, P=0	5				
het trive allefted I = 1	(78 P = 088)					
			1 12 15 1 2	ś ii		
			Ferrustern Bill Ferrusse	a a c		


Early EN vs. i.v. fluid/no EN: Mortality

Review: Early Edwarf Marton vs. delayed natrient intele Comparison: III Early EN vs. delayed natrient intele Outcome III Noteby

Sulp It sakategen	Sety Bi nili	lebyei nä	RPs(estadon) 99% C	Yegt S	1999 (cention) 19956-0	Ter
Nore	101	2/31	+ •	- 5.E	8.48 (0.05, 5.07)	1996
Crutecalul	1/21	2,17	+	5.91	0.27 (0.08, 2.37)	1996
State	4,121	4)12		17.82	1.05 [0.30, 3.66]	1998
Fupdic200	1011	5,118	++	6.88	0.33 [0.04, 2.45]	1990
Fupelie	1/39	1/38	+	6.74	0.14 (0.02, 1.08)	1971
Netoria	12,110	16/110		57.61	0.75 (0.37, 1.33)	1914
14(6%)	215	113	•	300.00	0.61 (0.37, 1.06)	
Table ents 31 (Exty Ox),						
	=1:11, #=5(?=0.54, ?=0	5				
Test to preal street I = 1	(78 P = 088)					
			11 12 15 1 2	5 TL		
			Finance Early Bill Finance de	9 K		

Early EN vs. i.v. Fluid /no EN: Infectious Complications

Review Early Exerci Nambor vs. Selayest namer i table (Newton 10) Exerciser III Early EX-as delayest namer i table Tactore III Intertises Carologions



Earl vs. Late EN: Infectious Complications

Review: Early Extensilitation vs. delayed nutrent intale (Nersion IC) Comparison: Of Early EX vs. delayed nutrent intale Solome: Of Intestous Complications

Stadiji m sada-cesteganji	Ențăl N	telejest til	Rif (randum) 1996 D	Wegtt S	彩(arden) 王称 0	Yer
litat	812	715		2.4	1.6 (1.9, 1.9)	2000
Carper 204	3(27	19/15		16.64	1.52 [1.2, 1.9]	201
Peci	11/14	LL(13	+	10.63	1.0 (1.7, 1.3)	2008
lçışını 👘	3/14	614		11.5	1.91 (1.15, 1.41)	2018
國際即	5	£	•	130.00	1.75 (1.5), 1.33)	
國 经专门 医约氏	Al (despect)					
Test for Metropriety: Dif	-83, d+3P+10,P+5	235				
Test for oversal effect 2 =	(B)(F=030)					
			éi iz iš i i	÷ 11		
			Forcus Gan Bl. Forcus de	bet .		

No influence on: Ventilator days, LOICUS, LOHS

Message 2: Early vs. Late EN

The problem with randomised studies in all the nutritional literature is the lack of a proper methodology leading to a high risk of bias => over estimation of treatment effects

Despite of that:

Repetitive frequent findings of **beneficial** effects of early EN (< 24h)

EN complications

- Abdominal distension
- o Diarrhea
- Intestinal necrosis (intrajejunal feeding)
- Tracheal aspiration
- Mechanical complication

Timing of PN

- Patients who can be fed adequately within the first 3 days do not need PN
- Malnourished patients with partial GI intolerance profit from pre- and earlier (> 24-36 h) supplementing PN
- Patients with prolonged (partial) GI-intolerance profit from PN supplementation
 - Not immediately after the admission
 - If ever possible, a minimum of enteral (immuno-) nutrition should be given

EN vs EN+PN: Systematic Review

- 5 studies; in all studies EN and PN were started simultaneously
 - No significant effect on mortality by combining EN + PN
 - No effect on infectious complications, LOHS, ventilator days

CONCLUSION: In critically ill patients without malnutrition und with working GI tract simultaneous start of EN and PN is useless compared to EN alone

Dhaliwal R et al. Intensive Care Med. 2004; 30:1666-71

Clinical Nutrition 28 (2009) 387-400



ESPEN Guidelines on Parenteral Nutrition: Intensive care

Pierre Singer^a, Mette M. Berger^b, Greet Van den Berghe^c, Gianni Biolo^d, Philip Calder^e, Alastair Forbes^f, Richard Griffiths^g, Georg Kreyman^h, Xavier Leverveⁱ, Claude Pichard^j

- All patients who are not expected to be on normal nutrition within 3 days should receive PN within 24–48 h if EN is contraindicated or if they cannot tolerate EN. (Grade C)
- In the absence of indirect calorimetry, ICU patients should receive 25 kcal/kg/day increasing to target over the next 2–3 days (Grade C)
- All patients receiving less than their targeted enteral feeding after 2 days should be considered for supplementary PN (Grade C)

PN complications

- Mechanical
- Infectious
- Metabolic

••• Insulin resistance

Stress hormones

- Catecholamines
- Cortisol
- Glucagon
- (Growth hormone)

Cytokines


- TNF alpha
- Interleukin-6

••• Insulin resistance


Reduced effect of insulin on glucose turnover –
 Hyperglycemia

Related to


- Substrate oxidation
- Lipolysis
- Protein catabolism



Thorell et al: Curr Opin Clin Nutr Metab Care, 1999



Thorell et al: Curr Opin Clin Nutr Metab Care, 1999



Thorell et al: Curr Opin Clin Nutr Metab Care, 1999


• • • Factors predicting length of stay

- Type of surgery
- Perioperative blood loss
- o Postoperative insulin resistance

R² = 0.71, p < 0.01


Thorell et al: Curr Opin Clin Nutr Metab Care, 1999

Risk of hyperglycemia



BG levels were strongly corelated with severity of septic shock estimated by APACHE II score (r=+0.241;p=0.005) or SAPS II (r=0.280;p=0.001) - Pearson Correlation

Mirea L et al. Discontinuous corticosteroids administration increase the risk of hyperglycaemia in septic shock, Clinical Nutrition 2014; 33: S125 Mirea L et al. The impact of corticosteroids administration in septic shock on glycaemic variability, Crit Care 2014; A333



Mirea L et al. Discontinuous corticosteroids administration increase the risk of hyperglycaemia in septic shock, Clinical Nutrition 2014; 33: S125 Mirea L et al. The impact of corticosteroids administration in septic shock on glycaemic variability, Crit Care 2014; A333

Glycaemic variability


		_	deces		
			da	nu	Total
grupSD	p20	Frecventa	42	20	62
		% din grupSD	67,7	32,3	100,0
		70 ani grapo D	%	%	%
		% din deces	73,7	26,0	46,3
			%	%	%
	s20	Frecventa	15	57	72
		% din grupSD	20,8	79,2	100,0
			%	%	%
		% din deces	26,3	74,0	53,7
			%	%	%
Total		Frecventa	57	77	134
		% din grupSD	42,5	57,5	100,0
			%	%	%
		% din deces	100,0	100,0	100,0
			%	%	%

Mirea L et al. The impact of corticosteroids administration in septic shock on glycaemic variability, Crit Care 2014; A333

Insulin treatment in surgical ICU

Prospective randomized trial 1548 consecutive postop ICU patients Target glucose 4.5-6.1 mM vs. treat >12mM

Mortality ICUMortality in hospital



G van den Berghe, N Engl J Med 2001

Insulin treatment in surgical ICU




Prospective randomized trial

- 1548 consecutive postop ICU patients
- Target glucose 4.5-6.1 mM vs. treat >12mM
- Bacteremia
- Ventilatory support
- Renal failure
- Polyneuropathy


46%
37%
41%
44%

G van den Berghe, N Engl J Med 2001

• • VISEP Trial, 2008



Brunkhorst FM, Engel C, Bloos F, et al. N Engl J Med 2008, 358:125-139



Finfer S et al. N Engl J Med 2009;360:1283-97

NICE SUGAR 1

В						
Subgroup	Intensive Control (N=3010)	Conventional Control (N=3012)	Odd	s Ratio for Death (95% CI)	P Value for Heterogeneity
	no. of deaths/no	. with data availabl	le			
Operative admission						0.10
Yes	272/1111	222/1121			1.31 (1.07–1.61)
No	557/1898	529/1891			1.07 (0.93–1.23)
Diabetes						0.60
Yes	195/615	165/596			— 1.21 (0.95–1.55)
No	634/2394	586/2416	÷		1.12 (0.99–1.28)
Severe sepsis		<				0.93
Yes	202/673	172/626			1.13 (0.89–1.44)
No	627/2335	579/2386	-		1.15 (1.01–1.31)
Trauma						0.07
Yes	41/421	57/465			0.77 (0.50–1.18)
No	788/2587	694/2547		—— — —	1.17 (1.04–1.32)
APACHE II score						0.84
≥25	386/927	363/944			1.14 (0.95–1.37)
<25	442/2080	387/2066	-		1.17 (1.01–1.36)
Corticosteroids						0.06
Yes	134/392	140/378			0.88 (0.66–1.19)
No	695/2616	611/2634		—— — —	1.20 (1.06–1.36)
All deaths at day 90	829/3010	751/3012			1.14 (1.02–1.28) 0.02
		0	.6 0.8 1.0	0 1.2 1.4	1.6	
			Intensive Control Better	Conventional Control Better	-	

Finfer S et al. N Engl J Med 2009;360:1283-97

• • • NICE SUGAR 2

Subgroup	Deaths	Hazard Ratio (95% CI)	P Value
	no.		
Cardiovascular cause of death			
Distributive shock			
No hypoglycemia	110	1.00	
Moderate hypoglycemia	177	- 2.34 (1.69-3.25) <0.001
Severe hypoglycemia	21	4.35 (2.49-7.61) <0.001
Arrhythmia			
No hypoglycemia	40	1.00	
Moderate hypoglycemia	41	1.31 (0.71–2.43) 0.38
Severe hypoglycemia	2	1.06 (0.23-4.86) 0.94
Other			
No hypoglycemia	96	1.00	
Moderate hypoglycemia	119	1.41 (0.98-2.08) 0.09
Severe hypoglycemia	8	1.29 (0.56-2.99) 0.55
Neurologic cause of death			
No hypoglycemia	203	1.00	
Moderate hypoglycemia	158) 0.36
Severe hypoglycemia	12	1.74 (0.90-3.36) 0.10
Respiratory cause of death			
No hypoglycemia	170	1.00	
Moderate hypoglycemia	179) 0.69
Severe hypoglycemia	19	1.42 (0.81-2.50) 0.22
Other cause of death			
No hypoglycemia	107	1.00	
Moderate hypoglycemia	100	1.46 (0.99-2.15) 0.05
Severe hypoglycemia	17	2.98 (1.51-5.88) 0.002
	0.12	1.00 8.00	

Finfer S et al. N Engl J Med 2012;367:1108-18

• • Metanalysis

Griesdale et al., 2009
Friedrich et al., 2010
Wiener et al., 2008
Marik et al., 2010
Kansagara et al., 2011

Griesdale DE, de Souza RJ, van Dam RM, et al. CMAJ 2009; 180:821–827 Friedrich JO, Chant C, Adhikari NK. Crit Care 2010; 14:324 Wiener RS, Wiener DC, Larson RJ. JAMA 2008; 300:933–944 Marik PE, Preiser JC. Chest 2010; 137:544–551 Kansagara D, Fu R, Freeman M, et al. 154:268–282




Preiser JC "Restoring normoglycemia: not so harmless"


(Crit Care 2008, 12:116)

Actual recommendations

- Start insulin drip protocol when 2 consecutive BG > 180mg/dL
- Glucose goal \leq 180 mg/dL, not \leq 110 mg/dL BG
- monitoring every 1-2 hour until stable, then q4hrs after
- Capillary BG may not be as accurate as blood BG

Dellinger RP, Gerlach H, Douglas I et al. Surviving Sepsis Campaign Critical Care Medicine 2013; 41(2): 580- 640, www.ccmjournal.org





major energy source for endothelial cell -Jing 2007 \downarrow ALI / ARDS in sepsis - Singleton 2005 protection to oxidative stress - Kelly 2003


major energy source for miocyte - Kelly 2003 protection to ischemia-reperfusion injury - Khogali 2002

glutathione synthesis regulatory for nitrogen metabolism - Kelly 2003

major energy source for mucosal cell, ↑ IgA -Singleton 2007 maintains structure (van der Hulst 1993), integrity and permeability of intestinal mucoasa - de Souza 2005 protection to oxidative stress, antiapoptotic -Singleton 2007

major energy source
stimulates PMN and macrophages - Singleton 2007
↓ Synthesis of proinflammatory citokines and peroxide

acid-base regulation NH_3 metabolism




modified after Kelly & Wischmeyer 2003

Pa Mo

Parenteral Glutamine vs Control Mortality

Study


- Dechelotte 2006
- Fuentes-Orozco 2004
- Griffiths 1997
- Powell-Tuck 1999
- Wischmeyer 2001
- Xian-Li 2004
- Ziegler unpub



Parenteral Glutamine vs Control Infectious Complications

Study


- Dechelotte 2006
- Fuentes-Orozco 2004
- Griffiths 1997
- Wischmeyer 2001
- Zhou 2004
- Ziegler unpub



Parenteral Glutamine vs Control Length of Hospital Stay

Study

- Fuentes-Orozco 2004
- Powell-Tuck 1999
- Wischmeyer 2001
- Xian-Li 2004
- Zhou 2004
- Ziegler unpub



Safety and Tolerance

 No study ever demonstrated any adverse effects at Gln supplementation in healthy volunteers or in patients (critically ill, surgical, etc)!

Avenell A. Proc Nutr Soc 2006;65:236-241.

- Even supra-physiological levels are well tolerated Albers S et al. Clin Sci 1988;75:463-468.
- Ideally: monitoring daily plasma levels (concentration > 0.42 mmol/l) → only for detecting lower levels Wernerman J. Clin Nutr Suppl 2004;1:37-42.
- Patients with severe head trauma (GCS<8 and cerebral edema) GIn supplementation doesn't modify intracerebral glutamate !!!
 Berg A et al. Intens Care Med 2006;32:1741-1746.

Guidelines & Recommendations


- All patients on parenteral nutrition should receive supplemental parenteral glutamine.
- In patients on enteral nutrition, parenteral glutamine might be supplemented.
- There is not enough evidence up to now to recommend enteral glutamine supplementation in all critically ill patients.
- Enteral glutamine is recommended in trauma and burn patients.

0.2 - 0.57 g/kg/day, starting within first 24 hs, for at least 7 days

Goeters C et al. Crit Care Med 2002;30:9

Glutamine supplementation


A. Glutamine supplementation



B. Standard supplementation

Grintescu I et al. The influence of parenteral glutamine supplementation on glucose homeostasis in critically ill polytrauma patients—A randomized-controlled clinical study, Clinical Nutrition 2014 (articol in press)

Glutamine supplementation



Grintescu I et al. The influence of parenteral glutamine supplementation on glucose homeostasis in critically ill polytrauma patients—A randomized-controlled clinical study, Clinical Nutrition 2014 (articol in press)

Conclusions- EN

- If EN is started early, a higher proportion of ICU patients can be adequately nourished enterally after a few days
- The literature suggests that EN should be started within the first 24 hours
- Only a few CI for EN
- Not so severe complications

Conclusions- TPN

- Severe complications
- Not reduce mortality and overall morbidity
- Expensive

Thank you!

14-16 noiembrie 2014 Al 15-lea Simpozion Național de Nutriție Clinică



1-7 November 2015 – București European Course of Clinical Nutrition

